logo-loader

AIM ImmunoTech reveals most recent advancements with its potential coronavirus treatment

Published: 10:32 13 Apr 2020 EDT

AIM ImmunoTech Inc (NYSE American: AIM) CEO Thomas Equels tells Proactive the Florida-based biopharma group is working on setting up its pre-clinical structure to allow it to begin clinical trials to treat the coronavirus with its lead drug Ampligen.

What's more, Equels says the firm recently inked a deal to research vaping devices as a vehicle for Ampligen to treat the coronavirus.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 9 minutes ago